Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Nov 14, 2019 · 10-Q · 45 days after period end · 0001564590-19-043378
| Metric | Q3 2019 | Q3 2018 |
|---|---|---|
| Net Income | -$16.54M | -$8.94M |
| EPS Diluted | -$0.97 | -$8.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end
